2022-05-05| Special

The FDA Issued its First Formal Warning to Companies Selling Delta-8 THC Products

by Reed Slater
Share To

The United States Food and Drug Administration announced on May 4 that it had sent warning letters to five American companies illegally selling cannabidiol (CBD) and Delta-8 THC products that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA focused mainly on the marketing and distribution of Delta-8 THC, stating that there are currently no FDA-approved drugs containing the compound. 


Related Article: Spotlight: Cannabidiol (CBD) Based Medication Heralds New Promise in Neurological Therapies


Beginning a Crackdown on Delta-8 Commercialization


The FDA has issued warning letters to many companies in the last several years regarding CBD commercialization. Still, the FDA’s most recent warning to five companies is the first time it has issued warnings regarding Delta-8. The FDA mentioned in yesterday’s warning that one of the concerns is the illegal marketing of Delta-8 for medicinal uses, despite not being FDA approved.

GO Prime with only $1.49 now

Absci Accelerates Breakthroughs in AI-Designed Drugs with AstraZeneca and Almirall Collaborations
Saving Lives Through Communication, Heroic Faith Medical Science Showcasing Novel AI Auscultation Tool for Procedural Sedation Patients in PGA 77
AbbVie Invests $10.1 Billion in ImmunoGen, Targeting the Ovarian Cancer Landscape
PRISM BioLab and Eli Lilly Join Forces in Revolutionary Drug Discovery Collaboration
Novel Hydrogel Delivery System Could Reduce Daily Diabetes Injections to Three Times a Year
Unveiling the Role of Microbes in Climate Change at COP28
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
Scroll to Top